Anti-Mouse VEGF Monoclonal Antibodies

PA007514.m2a: In Vivo Grade Recombinant Anti-mouse VEGF Monoclonal Antibody (Clone: G6-23), Mouse IgG2a Kappa

The in vivo grade recombinant anti-mouse VEGF mouse IgG2a kappa monoclonal antibody was produced in mammalian cells. 
Clone: G6-23.
Isotype: Mouse IgG2a Kappa.
Specificity/Sensitivity: The in vivo grade recombinant mouse monoclonal antibody (clone: G6-23) specifically binds to mouse VEGF.
Applications: ELISA, flow cytometry, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by the mouse VEGF protein. 
Formulation: 0.2 μM filtered solution of 1x PBS.
Purity: >95% by SDS-PAGE under reducing conditions.
Endotoxin Level: Less than 1 EU/mg of protein as determined by LAL method.

Shipping: The in vivo grade recombinant anti-mouse VEGF antibodies (clone of G6-23) are shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month from date of receipt, 2 to 8°C as supplied.

References of anti-mouse VEGF antibody (Clone: G6-23):

A VEGFR2–MICA bispecific antibody activates tumor-infiltrating lymphocytes and exhibits potent anti-tumor efficacy in mice
Xu, Y., et al. Mol Cancer Ther. 2024 Aug 2;23(8):1069-1082. doi: 10.1158/1535-7163.MCT-23-0564. PMID: 38791979
We examined the anti-VEGF-B-specific monoclonal antibody 2H10 in preclinical xenograft models of breast and colorectal cancer, in comparison with the anti-VEGF-A antibody bevacizumab. Cell surface expression of VEGFR-1 (orange) and VEGFR-2 (green) was explored in four cancer cell lines (DU4475, MDA-MB-231, COLO205, and HT29) by antibody staining and flow cytometry analysis. Tumor volumes were measured every 3 days, showing significant reduction in 2H10-treated groups compared to controls (P < 0.01). Immunohistochemistry confirmed reduced microvessel density in tumors from mice treated with anti-VEGF-B antibody. Survival analysis indicated a 25% increase in median survival in the 2H10 group compared to controls.
Tags: anti-mouse VEGF G6-23; anti-mouse VEGF G6-23 mAb

Targeting tumor vasculature to improve antitumor activity of T cells armed ex vivo with T cell engaging bispecific antibody
Park, J. A., et al. J Immunother Cancer. 2023 Apr;11(4):e006150. doi: 10.1136/jitc-2022-006150. PMID: 36990507
Anti-human VEGF (bevacizumab, BVZ) or anti-mouse VEGF antibody (B20-4.1.1) was used as VEGF blockade, and ex vivo armed T cells (EATs) carrying anti-GD2, anti-HER2, or anti-glypican3 (GPC3) IgG-(L)-scFv platformed BsAb were used. Tumor growth inhibition was observed in 80% of mice receiving combined GD2-EATs and B20-4.1.1 treatment. Flow cytometry revealed increased CD8+ T cell infiltration in tumors from B20-4.1.1-treated mice. High endothelial venules (HEVs) were induced in tumors by combined GD2-EATs and anti-VEGF therapy. VEGF levels in mouse serum were quantified using VEGF Quantikine ELISA Kit post-treatment.
Tags: anti-mouse VEGF G6-23 antibody in vivo; anti-mouse VEGF G6-23 in animal model

Neutralization of the induced VEGF-A potentiates the therapeutic effect of an anti-VEGFR2 antibody on gastric cancer in vivo
Kang, W., et al. Am J Cancer Res. 2021 Mar 15;11(3):879-895. PMID: 33791159
Anti-mouse VEGF-A antibody (B20-4.1.1, 800 μg/mouse) was administered intraperitoneally twice weekly for 3 weeks in MKN45 gastric cancer xenografts. Tumor volume was measured every 3 days using a caliper, showing significant reduction in B20-4.1.1-treated groups compared to controls (P < 0.05). Combined treatment with anti-VEGF-A and DC101 reduced microvessel density by 60% in tumor sections, as assessed by CD31 staining. Serum VEGF-A levels were quantified by ELISA, showing a 45% decrease in B20-4.1.1-treated mice. Kaplan-Meier analysis indicated improved survival in mice receiving dual VEGF-A/VEGFR-2 blockade.
Tags: anti-mouse VEGF G6-23 mAb in animal model; anti-mouse VEGF G6-23 in cancer research

Combined VEGFR2 and PD-L1 blockade in renal cell carcinoma
Manning, E. A., et al. Cancer Immunol Res. 2017 Nov;5(11):1008-1018. doi: 10.1158/2326-6066.CIR-17-0201. PMID: 29084200
Anti-mouse VEGF antibody (B20-4.1.1, 5 mg/kg i.p. weekly) was administered alone or in combination with anti-PD-L1 in RENCA syngeneic tumor models. Tumor vessel density was reduced by 55% in B20-4.1.1-treated mice, as confirmed by immunohistochemistry. Flow cytometry analysis showed increased infiltration of CD8+ T cells in tumors from B20-4.1.1-treated mice. Combination therapy prolonged median survival by 25 days compared to single-agent treatments. Peripheral immune cells were assessed for PD-L1 expression, revealing upregulation post-B20-4.1.1 administration.
Tags: anti-mouse VEGF G6-23 mAb in cancer research; anti-mouse VEGF (G6-23) in vivo antibody

VEGF blockade enables oncolytic cancer virotherapy in part by modulating intratumoral myeloid cells
Chaurasiya, S., et al. Mol Ther. 2013 Jun;21(6):1014-23. doi: 10.1038/mt.2013.39. PMID: 23481323
Tumor-bearing animals were treated with either PBS (control) or oHSV by intratumoral injection and intraperitoneal IgG (control) or anti-mouse VEGF antibodies B20-4.1.1 or bevacizumab. Tumors were harvested on day +3 and analyzed for tumor-derived hVEGF and host-derived mVEGF levels by ELISA. Flow cytometry showed a significant reduction in CD11b+ myeloid cells in B20-4.1.1-treated tumors. Anti-VEGF antibodies enhanced the antitumor effects of virotherapy, in part due to decreased angiogenesis. MHC class II-positive macrophages were quantified by flow cytometry in treated tumors.
Tags: anti-VEGF clone G6-23; clone G6-23 of anti-mouse VEGF mAb

For more references about anti-mouse VEGF antibody (Clone: G6-23), please contact our scientific support team with message@sydlabs.com.

Related Recombinant IgG Reference Antibodies:
In vivo grade recombinant mouse IgG2a isotype control antibody

Syd Labs provides the following anti-mouse VEGFA monoclonal antibodies:
In vivo grade recombinant anti-mouse VEGFA monoclonal antibodies (Clone B20-4.1.1.1))
In vivo grade recombinant anti-mouse VEGF-A monoclonal antibodies (Clone G6-31)
In vivo grade recombinant anti-mouse VEGF monoclonal antibodies (Clone G6-23)

Syd Labs provides the following anti-mouse PD-1 / VEGFA bispecific antibodies:
In vivo grade recombinant anti-mouse PD-1 / VEGF-A bispecific antibodies (Clone RMP1-14.1 / B20-4.1.1.1)
In vivo grade recombinant anti-mouse PD1 / VEGFA bispecific antibodies (Clone 29F.1A12.1 / B20-4.1.1.1)
In vivo grade recombinant anti-mouse PD-1 / VEGF bispecific antibodies (Clone RMP1-14.1 / G6-23)
In vivo grade recombinant anti-mouse PD1 / VEGF bispecific antibodies (Clone 29F.1A12.1 / G6-23)
In vivo grade recombinant anti-mouse PD 1 / VEGF bispecific antibodies (Clone RMP1-14.1 / G6-31)
In vivo grade recombinant anti-mouse PD-1 / VEGF A bispecific antibodies (Clone 29F.1A12.1 / G6-31)

Syd Labs provides the following anti-mouse PD-L1 / VEGFA bispecific antibodies:
In vivo grade recombinant anti-mouse PD-L1 / VEGF-A bispecific antibodies (Clone 10F.9G2.1 / B20-4.1.1.1)
In vivo grade recombinant anti-mouse PD-L1 / VEGF bispecific antibodies (Clone 10F.9G2.1 / G6-23)
In vivo grade recombinant anti-mouse PDL1 / VEGF bispecific antibodies (Clone 10F.9G2.1 / G6-31)

Syd Labs provides the following recombinant anti-mouse VEGF monoclonal antibodies for Flow Cytometry:
Recombinant Anti-mouse VEGF Monoclonal Antibody (Clone: B20-4.1.1.1) for Flow Cytometry
Recombinant Anti-mouse VEGF Monoclonal Antibody (Clone: G6-23) for Flow Cytometry
Recombinant Anti-mouse VEGF Monoclonal Antibody (Clone: G6-31) for Flow Cytometry

Syd Labs also provides the following anti-VEGF antibody biosimilar proteins:
Bevacizumab Biosimilar, research grade, anti-human VEGF monoclonal antibody
Bevacizumab Biosimilar, L234A L235A P329G (LALAPG) Fc silent mutant
Ramucirumab Biosimilar, research grade, anti-human VEGF / VEGFR2 / VEGFR-2 monoclonal antibody
Ranibizumab Biosimilar, research grade, anti-human VEGF monoclonal antibody
Brolucizumab Biosimilar, research grade, VEGF-A Monoclonal Antibody
Faricimab Biosimilar, research grade, Human ANGPT2/VEGFA Monoclonal Antibody